Ouh et al., [42] reported that adiponectin treatment of ovarian cancer cells induces angiogenesis via CXC chemokine ligand 1 independently of vascular endothelial growth factor (VEGF) and they suggested that adiponectin may serve as a novel therapeutic target for ovarian cancer. This evidence concerns the gene VEGFA and ovarian carcinoma.